Experienced in WT1-Related Wilms Tumor Syndromes

Dr. Harsha V. Poola

Hematology Oncology | Hematology | Oncology
Thedacare Incorporated
2500 E Capital Dr, 
Appleton, WI 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Experienced in WT1-Related Wilms Tumor Syndromes
Thedacare Incorporated
2500 E Capital Dr, 
Appleton, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Harsha Poola is a Hematologist Oncology specialist and a Hematologist in Appleton, Wisconsin. Dr. Poola is rated as an Experienced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Thrombocytopenia, Familial Colorectal Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Poola is currently accepting new patients.

His clinical research consists of participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in WI
Hospital Affiliations
Thedacare Regional Medical Center - Appleton Inc
Thedacare Regional Med Ctr - Neenah
Thedacare Medical Center - New London
Languages Spoken
English
Hindi
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare
  • OTHER COMMERCIAL
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Quartz
  • HMO
  • POS
  • PPO
Security Health
  • EPO
  • HMO
  • INDEMNITY
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

THEDACARE INCORPORATED
2500 E Capital Dr, Appleton, WI 54911

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: October 10, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Implementation and Effectiveness Trial of HN-STAR
Implementation and Effectiveness Trial of HN-STAR
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Other
Study Phase: Not Applicable
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Cheruppolil R. Santhosh-Kumar
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Cheruppolil R. Santhosh-Kumar
Hematology Oncology | Hematology | Oncology
1222 N 23rd St, 
Sheboygan, WI 
 (48.3 miles away)
920-457-6800
Languages Spoken:
English
See accepted insurances

Cheruppolil Santhosh-Kumar is a Hematologist Oncology specialist and a Hematologist in Sheboygan, Wisconsin. Dr. Santhosh-Kumar is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Paget Disease of the Breast, and Clear Cell Sarcoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew L. Ryan
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Matthew L. Ryan
Hematology Oncology | Hematology | Oncology

Ascension Ne Wisconsin, Inc

1506 S Oneida St, 
Appleton, WI 
 (2.5 miles away)
920-738-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Matthew Ryan is a Hematologist Oncology specialist and a Hematologist in Appleton, Wisconsin. Dr. Ryan is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Lung Adenocarcinoma, Acquired Hemophilia, Bone Marrow Aspiration, and Gastrostomy. Dr. Ryan is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian L. Burnette
Hematology Oncology | Hematology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Brian L. Burnette
Hematology Oncology | Hematology | Oncology

St Vincent Hospital-Hospital Sisters-Third Order Of St Francis

835 S Van Buren St, 
Green Bay, WI 
 (23.7 miles away)
920-433-0111
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Brian Burnette is a Hematologist Oncology specialist and a Hematologist in Green Bay, Wisconsin. Dr. Burnette is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Large-Cell Immunoblastic Lymphoma, Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Bone Marrow Aspiration. Dr. Burnette is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Poola's expertise for a condition
ConditionClose
      View All 24 Advanced Conditions
      View All 185 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile